ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016

Go back to ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016

Macquarie Upgrades ResMed (RMD) to Neutral

April 28, 2016 7:08 AM EDT

Macquarie upgraded ResMed (NYSE: RMD) from Underperform to Neutral.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $56.65 yesterday.

... More

Piper Jaffray Downgrades ResMed (RMD) to Neutral

April 27, 2016 6:37 AM EDT

Piper Jaffray downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $57.00 (from $65.00).

Analyst Matt O'Brien commented, "We are downgrading RMD to Neutral from Overweight and lowering our PT to $57 from $65. The genesis of our downgrade is that we believe headwinds and the lack of near term... More

ResMed (RMD) Misses Q3 EPS by 1c

April 26, 2016 4:14 PM EDT

ResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

... More